Compare AbbVie Inc (ABBV) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Kinder Morgan Inc — how do they compare? AbbVie Inc trades at $253.64 (market cap $449.91B), while Kinder Morgan Inc trades at $32.37 (market cap $72.28B). The key difference: AbbVie Inc is far larger — about 6.2× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| ABBV | KMI | |
|---|---|---|
Market Cap | $449.91B | $72.28B |
Sector | Health | Energy |
52-Week High | $261.07 | $34.31 |
52-Week Low | $184.85 | $25.84 |
Enterprise Value | $513.38B | $104.16B |
Dividend Yield | 2.72% | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
KMI trades at $32.49, up 1.34% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and maintains a solid dividend of $0.30 per share. Revenue grew to $16.94B in 2025, with net income reaching $3.06B, reflecting an 18.04% margin. Analyst consensus is mixed, with 47% buy ratings and 50% hold.
KMI's outlook is supported by stable cash flows from fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure. Key risks include high debt levels and exposure to energy market volatility. The stock offers income potential with a near 4% yield, but investors should monitor execution on growth projects and commodity price trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
